Liraglutide
LR10 · 10mg · 2026-08-16 · N/A
COA PDF ↗
LR10Images are illustrative. Actual specifications are as selected and confirmed in writing.
GLP-1 & Metabolic Research
Liraglutide
Weight reduction and weight maintenance
Liraglutide specifications and reference prices. Select a specification to add it to your cart.
10mg*10vials
Reference priceUS$164.71
For laboratory research only. Not for human or veterinary use.
COA 检测报告 / Reports
Compare all specifications & reference prices
| SKU | Specification / pack | Reference price (USD) |
|---|---|---|
| LR10 | 10mg*10vials | US$164.71 |
Temporarily sold-out specifications can still be added to an inquiry to ask about restocking. An inquiry is not an order or an agreed price.
DOCUMENTATION / LR10
Liraglutide — supplied COA and inquiry notes
The Liraglutide catalog group currently lists 1 specification. Use the selector and specification table above to compare SKUs and reference prices. The linked report identifies sample LR10; its sample code is not a separate specification selection.
- Report sample code
- LR10
- Reported date
- 2026-08-16
- Sample purity (HPLC-UV)
- 99.82%
- Sample net content
- 12.16 mg
- Lot / batch field
- N/A
- Endotoxin result
- N/A
These values describe the supplied test sample only.
When inquiring about Liraglutide, include the exact SKU, pack quantity and destination. Ask for stock and batch-document confirmation. Temporarily sold-out specifications can still be queried; the cart is not a confirmed order.
For laboratory research only. Not for human or veterinary use. The supplied report footnotes also exclude diagnostic, therapeutic and clinical applications.
Explore GLP-1 & Metabolic Research ↗ · View all products
RESEARCH FOCUS
Main Uses & FAQs
This page organizes directly related information on weight loss and weight maintenance of Liraglutide. First, look at the research questions and findings, then verify the population or species, study preparations, and scope of interpretation.
Main TopicsWeight Loss · Weight Maintenance
USAGE REFERENCE
Liraglutide · Usage reference (for research purposes)
The following presents common research-context references for reconstitution, storage, dosage and cycles. The following presents common references in research settings. This page does not constitute advice for use in humans or animals.
🧪Reconstitution
- Suggested Diluent
- Bacteriostatic Water (containing 0.9% benzyl alcohol); some peptides may use sterile water or acetic acid to aid dissolution. See the individual product descriptions.
- Diluent Volume
- Slowly introduce the diluent along the vial wall until the lyophilized powder is covered. A common example is 5 mg reconstituted with 2 mL of bacteriostatic water, yielding approximately 2.5 mg/mL. Referenced reconstitution volumes are approximately 1–2.5 mL, with 2 mL commonly used. It is suggested to select and record a fixed volume based on the COA supplied with the purchase.
- Handling Notes
- Introduce the diluent slowly along the vial wall rather than directly onto the lyophilized powder. Leave it for 60–90 seconds to dissolve naturally; do not shake vigorously.
💾Storage
- Unreconstituted Lyophilized Powder
- Refrigerate at 2–8°C, protected from light; avoid repeated freeze–thaw cycles.
- After Reconstitution
- Refrigerate at 2–8°C; a common recommendation is touse within 28 days; do not freeze.
- Transport
- For short periods, use insulated packaging with ice packs; avoid high temperatures and direct light.
📏Dosage Reference (Research)
| Purpose / Setting | Common Reference |
|---|---|
| Administration Route | Subcutaneous injection |
| Frequency | Once daily |
🔁Cycle
Once-daily subcutaneous injection, rotating abdomen/thigh.
View the Complete Usage Guide Library →Note: The above describes common research-context references, rather than clinical recommendations. Refer to the batch COA and research protocol. For research use only; not for human or animal use.
References
Read the Full Research Review ↗Research SummaryKey Findings
What research findings exist regarding Liraglutide on weight loss and weight maintenance?
Liraglutide group weight loss was better than placebo, supporting postoperative adjunct weight management. Another study reports: Liraglutide group showed greater weight reduction than placebo; some subjects were below their previous lowest postoperative weight.[1] ↗ [2] ↗
Before ReadingStudy populations, species, formulations and delivery conditions each have a defined scope. Research on an ingredient does not establish that this site's product batches have been validated for efficacy in humans or veterinary use.
Human Study2025REF. 01
What findings are there in trials of insufficient responders to weight loss surgery?
Research Findings
Liraglutide group weight loss was better than placebo, supporting postoperative adjunct weight management.[1] ↗
Study Design
48 adults with insufficient response after weight loss surgery; 12 months liraglutide randomized controlled trial.
Scope & Limitations
Specific postoperative population, small sample, and dropout situation; not general effects in the ordinary population.
View the Article Title and Full Citation＋
Liraglutide and Weight Loss Among Suboptimal Responders to Metabolic Bariatric Surgery: A Randomized Clinical Trial.
JAMA Network Open · Volume/Issue/Year 2025
First published 2025-10-01 · PMID 41160027
DOI 10.1001/jamanetworkopen.2025.39848
Study hierarchy according to design2025REF. 02
What do studies of postoperative weight regain populations show?
Research Findings
Liraglutide group showed greater weight reduction than placebo; some subjects were below their previous lowest postoperative weight.[2] ↗
Study Design
132 post-gastric bypass weight regain patients; 56-week randomized double-blind trial
Scope & Limitations
Completion rate affected by the pandemic; Limited to specific postoperative groups and includes lifestyle counseling.
View the Article Title and Full Citation＋
A randomized, double-blind, placebo-controlled trial of weight loss using liraglutide 3.0 mg for weight recurrence after Roux-en-Y gastric bypass.
Surgery for Obesity and Related Diseases: Official Journal of the American Society for Bariatric Surgery · Volume Issue Year 2025
First published 2024-09-10 · PMID 39401933
DOI 10.1016/j.soard.2024.08.037
Human Study2025REF. 03
Changes in BMI indicators in pediatric obesity randomized trial
Research Findings
Liraglutide improved BMI-related endpoints compared to placebo.[3] ↗
Study Design
6 to under 12-year-old obese children, randomized trial.
Scope & Limitations
2024 online/2025 issue; special conditions for children’s research, not a basis for self-medication.
View the Article Title and Full Citation＋
Liraglutide for Children 6 to <12 Years of Age with Obesity - A Randomized Trial.
The New England Journal of Medicine · Volume, Issue, Year 2025
First published 2024-09-10 · PMID 39258838
DOI 10.1056/NEJMoa2407379
Human Study2015 · Historical basic researchREF. 04
What did the SCALE weight management study observe?
Research Findings
The liraglutide group had an average weight loss of 8.4 kg, compared to 2.8 kg in the placebo group, with more participants reaching the weight loss threshold.[4] ↗
Study Design
3,731 overweight/obese adults without type 2 diabetes; 56-week SCALE trial
Scope & Limitations
2015 basic research, both groups received lifestyle interventions; no guarantee of individual effect.
View the Article Title and Full Citation＋
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
The New England Journal of Medicine · Volume, Issue, Year 2015
First published on 2015-07-02 · PMID 26132939
DOI 10.1056/NEJMoa1411892
Currently, 4 original studies related to the theme of this page have been selected. The number of studies includes different designs, populations, or preparations, not commercial clinical efficacy ratings. This page is a usage-oriented positive data selection, not a systematic review or dosing recommendation. Historical studies, combination preparations, and special models are all separately indicated.
GO DEEPER
↗What Questions Do These Studies Address?
Compare study populations, findings and scope.
Liraglutide · Frequently Asked Questions.
What research findings exist regarding Liraglutide on weight loss and weight maintenance?＋
Liraglutide group weight loss was better than placebo, supporting postoperative adjunct weight management. Another study reports: Liraglutide group showed greater weight reduction than placebo; some subjects were below their previous lowest postoperative weight.[1] ↗ [2] ↗
Can postoperative weight-loss results of liraglutide be directly extrapolated to the general population?＋
Not allowed. Postoperative weight regain or insufficient initial weight loss applies to specific populations; ordinary overweight/obese adults should refer to corresponding studies such as SCALE, with separate explanations for follow-up and lifestyle interventions.[1] ↗ [2] ↗ [4] ↗
Liraglutide—these conclusions apply to which study populations?＋
48 adults with insufficient response after weight loss surgery; 12 months liraglutide randomized controlled trial; 132 post-Roux-en-Y gastric bypass patients with weight regain; 56-week randomized double-blind trial; 6 to under 12-year-old obese children randomized trial. Specific post-surgery populations, small samples, and dropouts; not generalizable to the overall population.[1] ↗ [2] ↗ [3] ↗
VENTRO PEPTIDES & BIOTECH · RESEARCH PRODUCT RETAIL
Research peptides. Shop by product.
Compare specifications, reference prices and COA reports. Add products to your cart to request a quote.
QUALITY DOCUMENTSCOA BY PRODUCTGLOBAL DELIVERYTECHNICAL SUPPORT
01 / CATALOG
Browse products
Images are illustrative. Actual specifications are as selected and confirmed in writing.
GLP-1 & Metabolic Research
Semaglutide
10mg/vial x 10vials
US$90.91
Images are illustrative. Actual specifications are as selected and confirmed in writing.
GLP-1 & Metabolic Research
Tirzepatide
20mg/vial x 10vials
US$160.61
Images are illustrative. Actual specifications are as selected and confirmed in writing.
GLP-1 & Metabolic Research
Retatrutide
10mg/vial x 10vials
US$109.09
Images are illustrative. Actual specifications are as selected and confirmed in writing.
Repair & Recovery Research
BPC157
10mg/vial x 10vials
US$133.33
Images are illustrative. Actual specifications are as selected and confirmed in writing.
Longevity & Mitochondrial Research
MOTS-C
20mg/vial x 10vials
US$257.58Images are illustrative. Actual specifications are as selected and confirmed in writing.
GLP-1 & Metabolic Research
Liraglutide
10mg*10vials
US$164.71
Images are illustrative. Actual specifications are as selected and confirmed in writing.
Growth Hormone & IGF-1
IGF-lr3
1mg/vial x 10vials
US$505.8802 / DISCOVER
Browse categories
01 / 04
03 / ABOUT VENTRO
Reliable peptide supply, built for long-term partnerships.
Ventro supports research product retail purchases with clear pack specifications, available quality documents, and responsive international support.
- High-purity peptides
- Available COA reports
- COA & quality documentation
- Flexible small-quantity purchases
- Reliable global fulfillment
- Research product retail support
04 / QUALITY SYSTEM
Quality without compromise
Browse the available COA reports by product. Confirm documentation for your order with our team.
Controlled quality workflowRaw material to final release
Responsive global supportProduct matching and technical support
RESEARCH PRODUCT INQUIRY
Submit a product inquiry
Tell us the product, specification, and expected quantity. Our team will respond with pricing and available documents.